Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the DESTINY-Breast04 trial data, but adding the DESTINY-Breast06 data to the label ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

More widespread use of mammograms, along with the implementation of targeted hormone therapies more than 40 years ago, has ...

ACS's goal is to survey 100,000 Black women between ages 25 and 55 who have not had a cancer diagnosis across the U.S. to increase understanding of Black women's health amid sharp racial health ...

Lack of screening and limited treatment options mean that low- and middle-income countries face higher death rates despite ...